| Trial ID: | L0593 |
| Source ID: | NCT00530114
|
| Associated Drug: |
Amg 223
|
| Title: |
Study to Assess Fixed Dosing of AMG 223 in Subjects With Chronic Kidney Disease on Hemodialysis With Hyperphosphatemia
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
End Stage Renal Disease|Chronic Kidney Disease|Hyperphosphatemic|Kidney Disease
|
| Interventions: |
DRUG: AMG 223|DRUG: Placebo
|
| Outcome Measures: |
Primary: To demonstrate the AMG 223 will produce a statistically significant reduction in serum phosphorus compared with placebo over a 3 week treatment period in subjects with CKD receiving dialysis, TREATMENT PERIOD | Secondary: To describe a dose response for AMG 223, TREATMENT PERIOD|To evaluate the safety and tolerability of AMG 223, ENTIRE STUDY
|
| Sponsor/Collaborators: |
Sponsor: Amgen
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
167
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2008-03
|
| Completion Date: |
2009-02
|
| Results First Posted: |
|
| Last Update Posted: |
2016-03-14
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00530114
|
